Anti-CD19 redirected NK cell therapy (National University Health System, Singapore)
N/A
Report date: 2022/07/19 20:00:45
Base Information
Drug NameAnti-CD19 redirected NK cell therapy (National University Health System, Singapore)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational University Health System
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesNational University Health System
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A